Druce, PaigeCalanzani, NataliaSnudden, ClaudiaMilley, KristiBoscott, RachelBehiyat, DawnyaMartinez-Gutierrez, JavieraSaji, SmijiOberoi, JasmeenFunston, GarthMessenger, MikeWalter, Fiona M.Emery, Jon2023-01-182023-01-182021-06-01Druce, P, Calanzani, N, Snudden, C, Milley, K, Boscott, R, Behiyat, D, Martinez-Gutierrez, J, Saji, S, Oberoi, J, Funston, G, Messenger, M, Walter, F M & Emery, J 2021, 'Identifying Novel Biomarkers Ready for Evaluation in Low-Prevalence Populations for the Early Detection of Lower Gastrointestinal Cancers : A Systematic Review and Meta-Analysis', Advances in Therapy, vol. 38, no. 6, pp. 3032-3065. https://doi.org/10.1007/s12325-021-01645-61865-8652RIS: urn:6521C2898E25D8069758140171EC5302RIS: Druce2021ORCID: /0000-0002-5068-2543/work/126804476https://hdl.handle.net/2164/19856Funding This study was supported by the CanTest Collaborative (funded by Cancer Research UK C8640/A23385) of which Fiona M. Walter is Director, Jon Emery is an Associate Director, Mike Messenger is co-investigator, and Natalia Calanzani and Garth Funston are researchers. The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. Paige Druce, Kristi Milley and Jon Emery are supported by the Cancer Australia Primary Care Collaborative Cancer Clinical Trials Group (PC4). Mike Messenger is funded by the NIHR Leeds In Vitro Diagnostic Co-operative (UK). No Rapid Service Fee or Open Access fee was received by the journal for the publication of this article.341409650engSDG 3 - Good Health and Well-beingBiomarkersClinical practiceColorectal cancerEarly detectionLower gastrointestinal cancersPrimary careRC0254 Neoplasms. Tumors. Oncology (including Cancer)Pharmacology (medical)BiochemistryOncologyCancer Research UKC8640/A23385Supplementary InformationRC0254Journal article10.1007/s12325-021-01645-6http://www.scopus.com/inward/record.url?scp=85104895086&partnerID=8YFLogxK386